Investigating possible approval paths of individualized neoantigen based therapeutic vaccines from a regulatory perspective
Introduction: Mortality in cancer has declined during recent years due to more efficient cancer treatments. Some of the novel immunotherapies against cancer under development has a risk of lacking regulatory guidance for the approval, such as neoantigen-based therapeutic vaccines. Aim: The purpose o...
| Main Author: | |
|---|---|
| Format: | Others |
| Language: | English |
| Published: |
Uppsala universitet, Institutionen för farmaceutisk biovetenskap
2020
|
| Subjects: | |
| Online Access: | http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-416113 |